Posted by Michael Wonder on 07 Sep 2021
Reimbursement uncertain for Piqray targeting PIK3CA mutation in breast cancer
7 September 2021 - The first and only targeted therapy to treat hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer with PIK3CA gene mutation arrived in Korea recently.
However, it is uncertain whether it can get health insurance benefits.
